<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248427</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI1402</org_study_id>
    <nct_id>NCT03248427</nct_id>
  </id_info>
  <brief_title>Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.</brief_title>
  <acronym>CORALLEEN</acronym>
  <official_title>CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CORALLEEN is a two-arm, randomized, multicentric study in postmenopausal women with primary
      HR+/HER2 negative Luminal B breast cancer that will explore if the combination of ribociclib
      with letrozole offers clinical benefit at least comparable to that of standard chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel, two-arm, randomized 1:1, stratified by tumor size and nodal involvement,
      open-label, multicenter, exploratory study in postmenopausal women with primary operable
      HR+/HER2-negative Luminal B breast cancer according to PAM50 intrinsic subtype to evaluate
      the clinical benefit and biological effects of ribociclib combined with letrozole.

      The primary trial objective is to explore the clinical benefit of ribociclib plus letrozole
      versus chemotherapy.

      Luminal B patients will be randomized 1:1 to either letrozole plus ribociclib or
      chemotherapy.Two weeks after the first administration of the assigned treatment, patients
      will undergo a biopsy to assess early biological response to treatment, at Ki67 protein and
      gene expression level. After finalization of the assigned neoadjuvant treatment, patients
      will undergo surgery.

      The primary endpoint, Residual Cancer Burden, will be centrally assessed. Baseline, Day 15
      and post-treatment (surgical) primary breast tumor tissue samples should be available for
      each patient for molecular characterization A post-surgery visit will be performed within 28
      days (7 days) from surgery, and will mark the end of the study for that patient
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Residual Cancer Burden (RCB)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of residual cancer burden (RCB) score 0 or 1 (RCB0/1) after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per central assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Overall response rate (ORR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Tumor overall objective response rate (ORR), defined as the sum of Partial Responses (PR) and Complete Responses (CR) according to RECIST v1.1, as per Investigator's assessments by breast MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR in the breast and axillary lymph nodes</measure>
    <time_frame>24 weeks</time_frame>
    <description>pCR is defined as the complete absence of invasive carcinoma in the breast and axillary lymph nodes on histological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEPI Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Preoperative endocrine prognostic index (PEPI) score in the ribociclib plus letrozole treatment arm compared to historical values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breast conserving surgery (BCS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of breast conserving surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Ki67 in both treatment arms.</measure>
    <time_frame>At baseline, in week 2, and pre-surgery</time_frame>
    <description>Decrease in Ki67 in both treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, duration and severity of Adverse Events (AEs)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Incidence, duration and severity of Adverse Events (AEs) assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ribociclib + Letrozol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.</description>
    <arm_group_label>Ribociclib + Letrozol</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5mg</intervention_name>
    <description>Daily continuous</description>
    <arm_group_label>Ribociclib + Letrozol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60 mg/m2 as a continuous IV perfusion</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 MG/M2 in a 30 minutes IV infusion</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m2, in one hour IV infusion</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Signed Informed Consent Form prior to any study-specific procedure.

          2. Female patients.

          3. Post-menopausal status and age ≥18 years.

          4. Histologically confirmed invasive breast carcinoma, with all the following
             characteristics:

               -  Primary tumor ≥ 2cm in largest diameter as measured by breast MRI

               -  Stage I to stage IIIA breast cancer

               -  No evidence of distant metastasis (M0)

          5. Breast cancer eligible for primary surgery.

          6. Available pre-treatment FFPE core (Tru-cut) biopsy evaluable for PAM50 or possibility
             to obtain one. Minimal sample requirements are to have at least 2 tumor cylinders with
             a minimal tissue surface of 10 mm2 tissue, containing at least 10% tumor cells and
             having enough tissue to do at least 2 cuts of 10 micrometers each.

          7. Luminal B subtype as per PAM50 analysis of pre-treatment sample.

          8. ER-positive and/or PgR-positive and HER2-negative tumor by ASCO/CAP guidelines
             assessed locally.

          9. In the case of a multifocal tumor (defined as the presence of two or more foci of
             cancer within the same breast quadrant), the largest lesion must be ≥ 2 cm and
             designated the &quot;target&quot; lesion for all subsequent tumor evaluations and
             HR+/HER2-negative status must be documented in all the tumor foci.

         10. ECOG performance status of 0 or 1.

         11. Adequate hematological, renal and hepatic function.

         12. Ability and willingness to comply with study visits, treatment, testing and to comply
             with the protocol.

        Exclusion criteria

          1. Any prior treatment for primary invasive breast cancer.

          2. Inoperable locally advanced or inflammatory (i.e., inoperable Stage III) breast
             cancer.

          3. Metastatic (Stage IV) breast cancer.

          4. Bilateral invasive breast cancer.

          5. Multicentric breast cancer, defined as the presence of two or more foci of cancer in
             different quadrants of the same breast.

          6. Patients who have undergone sentinel lymph node biopsy prior to study treatment.

          7. Inability or unwillingness to swallow pills.

          8. Malabsorption syndrome or other condition that would interfere with enteric absorption
             of study drugs.

          9. Participation in a prior investigational study within 30 days prior to enrollment or
             within 5 half-lives of the investigational product, whichever is longer.

         10. Patient with a Child-Pugh score B or C.

         11. Patient has active cardiac disease or a history of cardiac dysfunction including any
             of the following:

               -  History of acute coronary syndromes (including myocardial infarction, unstable
                  angina, coronary artery bypass grafting, coronary angioplasty or stenting) or
                  symptomatic pericarditis within 12 months prior to screening.

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification III-IV).

               -  Documented cardiomyopathy.

               -  Patient has a Left Ventricular Ejection Fraction (LVEF) &lt; 50% as determined by
                  Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).

               -  Clinical significant cardiac arrhythmias (e.g. ventricular tachycardia), complete
                  left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz
                  type II and third-degree AV block)

               -  Long QT Syndrome or family history of idiopathic sudden death or congenital long
                  QT syndrome.

               -  On screening 12-lead ECG, any of the following cardiac parameters (defined as the
                  mean of triplicate ECGs: bradycardia (resting heart rate &lt; 50), tachycardia
                  (resting heart rate &gt; 90), PR interval &gt; 220 msec, QRS interval &gt;109 msec, or
                  QTcF interval ≥450 msec (using Fridericia's correction).

         12. Uncontrolled hypertension (Systolic blood pressure &gt;160 mmHg or &lt;90 mmHg and/or
             diastolic &gt;100 mmHg).

         13. Active infection requiring intravenous (IV) antibiotics.

         14. Symptomatic hypercalcemia despite adequate management.

         15. Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis.

         16. Known human immunodeficiency virus (HIV) infection.

         17. Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic
             dysfunction, physical examination finding, or clinical laboratory finding giving
             reasonable suspicion of a disease or condition that contraindicates the use of an
             investigational drug, that may compromise compliance with the protocol, that may
             affect the interpretation of the results, or renders the patients at high risk from
             treatment complications.

         18. Significant traumatic injury within 3 weeks prior to initiation of study treatment.

         19. Major surgical procedure (not including minor procedures such as lymph node biopsy,
             tumor core biopsy, fine needle aspiration) within 4 weeks prior to initiation of study
             treatment or not fully recovered from any side effects of previous procedures.

         20. Any psychological, familial, sociological, or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule.

         21. History of other malignancy within 5 years prior to screening, except for
             appropriately treated basal or squamous cell carcinoma, carcinoma in situ of the
             cervix, non-melanoma skin carcinoma, or Stage I uterine cancer.

         22. Hormone replacement therapy stopped less than 2 weeks before treatment start.

         23. Currently receiving or has received systemic corticosteroids until 2 weeks before
             treatment start or who have not fully recovered from side effects of such treatment.
             Following corticosteroid uses are permitted: single doses, topical applications (e.g.
             for rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local
             injections (e.g. intra-articular)

         24. Known hypersensitivity to any of the excipients of ribociclib, letrozole, doxorubicin,
             cyclophosphamide or paclitaxel.

         25. Patients currently on following medications, which cannot be interrupted 7 days prior
             treatment start:

               -  Any prohibited medication as per letrozole, doxorubicin, cyclophosphamide, or
                  paclitaxel label.

               -  Herbal preparations/medications, dietary supplements.

               -  Medications that have a known risk to prolong the QT interval or cause Torsades
                  de Pointe.

               -  Medications with a narrow therapeutic window and predominantly metabolized
                  through CYP3A4/5.

               -  Strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit
                  hybrids, pummelos, star-fruit and Seville oranges.

               -  Warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or
                  otherwise. Therapy with heparin, low molecular weight heparin or fondaparinux is
                  allowed.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleix Prat, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H.Clinic de Barcelona/</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquin Gavilá, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Instituto Valenciano de Oncología</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela Celiz, PhD</last_name>
    <phone>+346387844908</phone>
    <email>pamela.celiz@gruposolti.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montse Muñoz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier González Farré</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Saura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia l'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Miguel Gil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellón</name>
      <address>
        <city>Castelló</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Martínez Dueñas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Gonzalez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundació Privada Hospital Asil de Granollers</name>
      <address>
        <city>Granollers</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanesa Ortega</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura García Estevez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico MD Anderson International España</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Bratos Lorenzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucía González Cortijo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Rey Juan Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Hoyos Simón</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Ciruelos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación de Alcorcón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Jara Sánchez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Izarzugaza</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neus Ferrer Tur</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Lopez Lopez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Montaño</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Antonio Virizuela Echaburu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Gavilá</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begonia Bermejo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de València</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Llombart Cussac</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Luminal B tumors</keyword>
  <keyword>Ribociclib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

